Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
Pharmacoepidemiology and Risk Management 2024; 16(1): 1-10
Published online March 31, 2024 https://doi.org/10.56142/perm.24.0003
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
Hee-Jin Kim1, Dong Wook Kim2, Myeong Gyu Kim3,4, Mi-Sook Kim5, Ye-Jee Kim6, Jeong Ah Kim1, Suvin Park1, SeungJin Bae3,4, Aesun Shin7, Ju-Young Shin8, Song Vogue Ahn1, Jeonghoon Ahn1, Bo Ram Yang9, Heehyun Won1, Seung-Mi Lee10, Joongyub Lee7, Hui-Eon Lee4, Sun-Young Jung11, Haerin Cho1, Nam-Kyong Choi1,4
김희진1, 김동욱2, 김명규3,4, 김미숙5, 김예지6, 김정아1, 박수빈1, 배승진3,4, 신애선7, 신주영8, 안성복1, 안정훈1, 양보람9, 원희현1, 이승미10, 이중엽7, 이희언4, 정선영11, 조해린1, 최남경1,4
Correspondence to:Nam-Kyong Choi
Department of Health Convergence, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul 03760, Korea
Tel: +82-2-3277-6585
Fax: +82-2-3277-2867
E-mail: nchoi@ewha.ac.kr
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
While health insurance claims data in Korea have the potential as evidence for drug regulatory decision-making, its effective utilization remains limited. This study aims to identify the challenges encountered by researchers in utilizing claims data and discuss improvement strategies. We summarized practical difficulties encountered by researchers who have experience using claims data from the National Health Insurance Service and the Health Insurance Review and Assessment Service. Challenges encountered by researchers included difficulties in acquiring drug data, delays in data provision, limited provision of information on specific conditions, drugs, and treatments, small data capacity, short data usage periods, and spatiotemporal considerations when accessing data. To maximize the utility of claims data in drug regulatory decision-making, continuous communication between researchers and data providers is necessary for addressing these challenges.
KeywordsHealthcare administrative claims, Real-world data, Real-world evidence, Pharmaceutical research, Regulatory science